William C Dougall

List of Publications by Year
in descending order

18	1,533	566801 15	940134 16
papers	citations	h-index	g-index

20	20	20	2519
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	CD155 on Tumor Cells Drives Resistance to Immunotherapy by Inducing the Degradation of the Activating Receptor CD226 in CD8+ TÂCells. Immunity, 2020, 53, 805-823.e15.	6.6	79
2	The NK cell granule protein NKG7 regulates cytotoxic granule exocytosis and inflammation. Nature Immunology, 2020, 21, 1205-1218.	7.0	110
3	Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma. Clinical Cancer Research, 2020, 26, 3671-3681.	3.2	53
4	CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function. Cancer Immunology Research, 2019, 7, 559-571.	1.6	79
5	Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN). Trials, 2019, 20, 753.	0.7	20
6	The immune checkpoint CD96 defines a distinct lymphocyte phenotype and is highly expressed on tumorâ€infiltrating TÂcells. Immunology and Cell Biology, 2019, 97, 152-164.	1.0	29
7	Preoperative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC) (POPCORN).. Journal of Clinical Oncology, 2019, 37, TPS129-TPS129.	0.8	0
8	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. OncoImmunology, 2018, 7, e1431088.	2.1	67
9	CD96 targeted antibodies need not block CD96-CD155 interactions to promote NK cell anti-metastatic activity. OncoImmunology, 2018, 7, e1424677.	2.1	44
10	Deficiency of host CD96 and PD-1 or TIGIT enhances tumor immunity without significantly compromising immune homeostasis. OncoImmunology, 2018, 7, e1445949.	2.1	46
11	Roles of the RANKLâ€“RANK axis in antitumour immunity â€” implications for therapy. Nature Reviews Clinical Oncology, 2018, 15, 676-693.	12.5	77
12	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. OncoImmunology, 2018, 7, e1480301.	2.1	48
13	TIGIT immune checkpoint blockade restores CD8+ T-cell immunity against multiple myeloma. Blood, 2018, 132, 1689-1694.	0.6	198
14	CD155 loss enhances tumor suppression via combined host and tumor-intrinsic mechanisms. Journal of Clinical Investigation, 2018, 128, 2613-2625.	3.9	91
15	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer.. Journal of Clinical Oncology, 2018, 36, e21001-e21001.	0.8	0
16	<scp>TIGIT</scp> and <scp>CD</scp>96: new checkpoint receptor targets for cancer immunotherapy. Immunological Reviews, 2017, 276, 112-120.	2.8	351
17	Co-administration of RANKL and CTLA4 Antibodies Enhances Lymphocyte-Mediated Antitumor Immunity in Mice. Clinical Cancer Research, 2017, 23, 5789-5801.	3.2	70
18	Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy. Clinical Cancer Research, 2016, 22, 5183-5188.	3.2	171